Last reviewed · How we verify

NCT06317428: NTproBNP

NT-proBNP Levels During Triple Therapy With Formoterol/Glycopyrrolate/Budesonide in Patients With COPD.

Status unknown Last updated 19 March 2024
What this trial tests

trial in COPD in 29 participants. Status unknown.

Timeline
28 June 2022
Primary endpoint
31 December 2025
31 December 2025

Quick facts

Lead sponsorIstituto Nazionale di Ricovero e Cura per Anziani
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment29
Start date28 June 2022
Primary completion31 December 2025
Estimated completion31 December 2025
Sites2 locations across Italy

Conditions studied

Sponsor

Istituto Nazionale di Ricovero e Cura per Anziani — full company profile →

Who can join

50 and older, any sex, with COPD. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Observational prospective study to evaluate serum NT-proBNP levels in a population of COPD patients three months after the iniation of triple inhaled formoterol/glycopyrrolate/budesonide therapy.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for COPD

Currently open trials in the same condition.

Other Istituto Nazionale di Ricovero e Cura per Anziani trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06317428.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing